全球指数

CITIC PACIFIC(00267.HK):SCENARIO ANALYSIS FOR ASSET INJECTION

美银美林集团2014-03-27
CITIC Limited to go public through asset injection into CP
CITIC Pacific (CP) said it will acquire parent CITIC Limited (CL) (book value at Rmb225bn ) through both cash and n ew shares. The yet-to - be-decided price should dictate the ultimate investor reaction. IF CP can acquire CL at a reasonable price, we believe it should be a positive, as CP shareholders would own shares in a larger, flagship platform while concerns over cash flow pressure from Sino Iron project should ease. We maintain our Neutral rating but raise PO by 14% to HK$13 based on the potential elimination of the NAV discount as we expect covering of large short interest position, but new issue price to parent at HK$13.48/sh (6% above last closing price) could be a cap near term.
Acquisition scenario : HK$7- 25bn of public equity needed
Assuming CL will be priced between 0.6x (v CP at 0.5x, 0.76x P/B for listed CITIC Bank, 20% holdco discount) and 1.0 P/B, at the low end and with US$4bn debt, it would issue HK$131bn of equity to parent and HK$ 7bn in new equity to public to satisfy a 15% free float rule . At the high end , a 1x P/B price could mean HK$ 23bn of new public equity. Since most of CL’s assets are list ed and in currentl y out-of -favor sectors, we believe investors may demand an attractive valuation.
Transaction details and rationale
CL’s book value (ex CP stake) was Rmb225bn and profit was Rmb34bn in 2013. CL holds most of CITIC Group’s assets, including listed entities CITIC Bank (998 HK) , CITIC Securities (6030 HK) and CITI Resources (1205 HK) . While complicated, the transaction would likely enable CITIC Group to accomplish the twin results of going public but without creating yet another listed conglomerate platform apart from CP.
Regulatory hurdles ahead
We expect the transaction to take at least several months to unfold as it seems to be i n early stage. Independent shareholder approval will be needed, while the HKEx may deem CP a new listing applicant given the size of the injection.

免责声明

以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

推荐阅读

暂无数据

公司动态

    暂无数据

盘面综述

    暂无数据

IPO动态

    暂无数据

港股涨幅榜
  • 港股通
  • 红筹股
  • 国企股
  • 科技股
  • 名称/代码
  • 最新价
  • 涨跌幅

暂无数据

扫码关注

九方智投公众号

扫码关注

九方智投公众号